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Objective. We hypothesized that bone mineral density increase following bisphosphonates treatments may be explained by the
inﬂuence of the drug on the mechanical bone remodeling parameters.
Background. Patients treated with bisphosphonates continuously increase their bone mineral density. This increase is explained in
the ﬁrst 12–18 months following the treatment by the ﬁlling of the transient remodeling deﬁcit. Recently, results of a clinical study of
alendronate treatment over 7 years still show a continuous increase of bone mineral density. These results raised several questions
regarding our understanding of bisphosphonates mode of action.
Methods. Bone remodeling is inﬂuenced by diﬀerent factors including mechanical forces. In the present study, we propose then to
consider the eﬀect of bisphosphonates also under biomechanical considerations.
Results. Identiﬁcation of the model with the clinical data showed that daily treatment of 10 and 20 mg alendronate decreased the
bone turnover rate by 2% and 11%, respectively, in comparison with the 5 mg alendronate treatment. Moreover, the alendronate
treatments decreases the resorption threshold stimulus by 19% (25%, 28%) for the 5 mg (10 and 20 mg, respectively) compared to
placebo.
Conclusions. The increase of bone mineral density following bisphosphonates treatment may then be explained by biomechanical
considerations. Based on this description, bisphosphonates treatment may indeed change the susceptibility of bone to its bio-
mechanical environment decreasing the mechanical threshold where bone should undergo resorption.
Relevance
This model makes now possible to incorporate the eﬀect of the alendronate in ﬁnite element method studies of bone remodeling
allowing us to quantify the eﬀect of systemic alendronate treatment following a total hip replacement.
 2003 Elsevier Ltd. All rights reserved.
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In osteoporosis, bone resorption surpasses bone for-
mation activity resulting in bone loss (Boivin et al.,
2000). A rational approach to osteoporosis prevention is
therefore the use of drugs reducing bone resorption and
bone turnover. The underlying hypothesis is that inhi-* Corresponding author.
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doi:10.1016/j.clinbiomech.2003.10.002bition of bone resorption should enable bone formation
to restore bone mass to its homeostasis level, where it
should stabilize (Rodan, 1997). It should be kept in
mind however, that bone mass is also controlled by
mechanical forces.
Bisphosphonates such as alendronate received daily
have been shown to continuously increase patients bone
mineral density (Liberman et al., 1995) and to preserve
the biomechanical properties of the bone (Chavassieux
et al., 1997). At the cellular level, bisphosphonates
inactivate osteoclasts, which then undergo apoptosis,
Fig. 1. BMD evolution in function of the mechanical stimuli.
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over, and a positive bone balance (Fleisch, 1996). It has
been hypothesized that the reduced bone turnover in-
creases the life span of bone structural units and leads to
a more mature bone in which most units approach at
least a normal level in their degree of mineralization
(Meunier and Boivin, 1997). The lower bone turnover
allows the secondary mineralization to be achieved and
maintained resulting in an increased bone mineral den-
sity (BMD) (Boivin and Meunier, 1999). Based on these
observations, BMD increase in the ﬁrst 12–18 months of
antiresorptive drug treatment is explained by the ﬁlling
of the transient remodeling deﬁcit produced by the time
delay between completion of bone resorption and
completion of bone matrix formation with its minerali-
zation. Recently, it has been shown that alendronate
given without interruption for 7 years still increased
lumbar spine BMD (Tonino et al., 2000). This result
raises several questions regarding our understanding in
BMD increase following antiresorptive agents treatment
as the argument for the ﬁlling of the transient remod-
eling deﬁcit is no more a satisfactory explanation for
such a long treatment. An alternative explanation to the
BMD increase in long term bisphosphonates treatment
may be possible by taking into account biomechanical
considerations of bone remodeling.
Bone remodeling is inevitably linked to its bio-
mechanical environment. In the present study, a model
of bone remodeling including simultaneously the drug
and biomechanical eﬀects is then developed. Based on
this model, it is hypothesized that BMD increase fol-
lowing bisphosphonates treatments may be explained by
the inﬂuence of the drug on the bone remodeling para-
meters. If veriﬁed, this hypothesis would support the
idea that bisphosphonates treatment may indeed change
the susceptibility of bone to its biomechanical environ-
ment and would furnish a method of quantifying the
drug eﬀect on the bone remodeling. To test this hypoth-
esis, the parameters of the bone remodeling model are
identiﬁed with published data of alendronate phase III
treatment (Liberman et al., 1995).2. Methods
2.1. Biomechanical bone remodeling model
To relate bone adaptation to the mechanical stress
environment, it has been proposed to link the BMD
evolution d/
dt to its mechanical stimulus w by a piece wise
linear evolution relation (Fig. 1) (Carter, 1984; Huiskes
et al., 1987; Terrier et al., 1997). A lazy zone, where bone
neither resorbs nor densiﬁes is delimited by two thresh-
old stimuli wr and wd  vr and vd are respectively the bone
turnover rate in the resorption and densiﬁcation regime.
It should be noted that the value for the bone turnoverrate is diﬀerent for the resorption and the densiﬁcation
regime of the bone. The equation describing the bone
adaptation based on the piece wise linear evolution can
be generally expressed by (Terrier, 1999):
d/
dt
¼
vrðw wrÞ w < wr
0 wr6w6wd
vdðw wdÞ w > wd
8<
: ð1Þ2.2. Model of bisphosphonates eﬀect on bone remodeling
Bisphosphonates such as alendronate mainly aﬀect
the resorption process of bone turnover (Chavassieux
et al., 1997; Fleisch, 1996). We propose then to model
the eﬀects of bisphosphonates by aﬀecting the values of
the resorption parameters vr and wr, while the formation
parameters vd and wd are kept constant.
2.3. Determination of bisphosphonates eﬀect on resorption
parameters
To quantify the bisphosphonates eﬀect on the resorp-
tion parameters vr and wr, we used published data of an
alendronate phase III treatment (Liberman et al., 1995).
In this clinical trial, daily alendronate doses (placebo, 5,
10, and 20 mg) were orally given for two years to 994
postmenopausal women presenting osteoporosis. Mean
percentage changes in BMD measured at diﬀerent sites
were reported at regular intervals (0, 3, 6, 12, 18, and 24
months) and showed a continuous increase in the alendr-
onate groups correlated with the doses used.
The measured BMD can be broken down into the
contribution of the BMD due to bone formation minus
the BMD due to bone resorption. In case of alendronate
treatments (and under the assumption of a constant
biomechanical stimulus), bone formation should be
constant between all groups accordingly to the previ-
ously mentioned fact that bisphosphonates does not
inﬂuence the bone formation. The diﬀerences in the
measured BMD between groups could then only be
explained by a modiﬁcation of the bone resorption. We
used the measured BMD to determine the relative
Fig. 2. Mean (±SE) changes in bone mineral density of lumbar spine
from clinical study (M) (Liberman et al., 1995) and from simulation ðSÞ
with the biomechanical model presented.
Table 1
Error function values, ratios of wr-xmg=wr-placebo and vr-xmg=vr-5mg in
function of alendronate daily dose
Error (A, B) wr-xmg
wr-placebo
vr-xmg
vr-5mg
Placebo 1.7· 106 – –
5 mg 11.2· 106 0.81 –
10 mg 46.8· 106 0.75 0.98
20 mg 15.8· 106 0.72 0.89
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tween the diﬀerent treated groups. The values of the
measured BMD at the lumbar spine were used as stan-
dard errors were the lowest at this site.
In order to identify the resorption parameters, we
write Eq. (1) for the resorption situation. BMD evolu-
tion is then given by the following diﬀerential equation,
which can be used to ﬁt the clinical data (Terrier et al.,
1997):
d/
dt
/ðtÞ4 þ B/ðtÞ4  A ¼ 0
/ðt0Þ ¼ /0
8<
: ð2Þ
with /0 the BMD at time 0 and
A ¼ vrw
B ¼ vrwr

ð3Þ
Numerical methods are used to solve Eq. (2) from time
t0 ¼ 0 to time t ¼ 24 months in order to determine the A
and B values for the placebo and the treated groups. An
error function was then deﬁned as the quadratic sum of
the diﬀerence between the simulated BMD and mea-
sured BMD:
errorðA;BÞ ¼
X6
a¼1
½/mðtaÞ  /sðtaÞ2 ð4Þ
where /mðtaÞ is the measured BMD and /sðtaÞ is the
simulated BMD that depends on the choice of the A and
B parameters. Here ta ¼ 0, 3, 6, 12, 18, 24 months
for a ¼ 1; . . . ; 6. The FindMinimum function of
MathematicaTM (Wolfram Research, Inc., Champaign,
IL, USA) was used in order to ﬁnd the minimum value
of the error function and therefore to ﬁnd the value of
the two parameters (A and B) that produce the best ﬁt
between the simulated and measured BMD. This ap-
proach allows us to verify if the increase of BMD in
function of bisphosphonates treatment may be ex-
plained by biomechanical considerations.
It can be reasonably assumed that the mechanical
stimulus (which is a combination of physical activity
and body weight) did not signiﬁcantly diﬀer between
groups. The ratios of
B5mg;10mg;20mg
A5mg;10mg;20mg
 
Aplacebo
Bplacebo
 
ð5Þ
represent indeed the ratios of
wr-5mg;10mg;20mg
wr-placebo
: ð6Þ
As mentioned, the rate of bone turnover is diﬀerent in
the resorption and formation regime. The clinical data
of the alendronate phase III treatment can then be used
to quantify relative bone turnover rate within the
alendronate treatment. The ratiosA10mg;20mg
A5mg
ð7Þ
represent indeed the ratios of
vr-10mg;20mg
vr-5mg
ð8Þ
Calculation of these ratios allowed us to quantify the
doses eﬀect of alendronate on the resorption parameters
vr and wr.3. Results
Comparison of Eq. (2) with the measured BMD are
presented in Fig. 2. The simulated BMD closely ﬁts the
measured BMD. The error function values representing
the quadratic sum of the diﬀerence between the simulated
BMD and measured BMD for the placebo and alendro-
nate groups are reported in Table 1. Simulated placebo
BMD are quantitatively the closest to the mea-
sured BMD, followed by the 5 mg, 20 mg and ﬁnally 10
mg alendronate groups. Ratios between treatments
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treatment with 5 mg alendronate (10 and 20 mg, respec-
tively) decrease the resorption threshold stimulus (wr) by
19% (25%, 28%, respectively) compared to placebo. The
bone turnover rate (vr) was decreased by 2%, and 11%, for
the 10 and 20 mg treatments respectively compared to the
5 mg treatment.4. Discussion
Bone remodeling or bone mass are controlled by
diﬀerent factors including mechanical forces. The de-
scription of the drugs eﬀect on bone remodeling, as
bisphosphonates, should then be included in a biome-
chanical context. Indeed, as noted by Rodan (Rodan,
1997), bone mass changes in response to inhibitors of
bone resorption would depend on mechanical function.
We developed a model in which the eﬀect of a drug af-
fecting bone remodeling can be accounted for in a
general biomechanical approach.
The major result of this study is to show that the
alendronate treatment decreases the value of the re-
sorption threshold stimulus wr compared to placebo in a
dose dependant relationship. The eﬀect of alendronate
tends then to increase the lazy zone where no bone re-
modeling occurs. An extended lazy zone in the resorp-
tion part will then decrease the amount of bone
undergoing a resorption process. At a similar level of
mechanical stimulus, alendronate treatment will shift
the bone balance to an increase bone formation com-
pared to the situation before treatment.
The originality of this study is to quantify the eﬀect of
the drugs on bone remodeling with ﬁgures. New ways of
investigation may then be open to understand the eﬀect
of drug aﬀecting bone remodeling. It would be possible
to incorporate the eﬀect of alendronate in ﬁnite elements
method studies of bone remodeling allowing us for ex-
ample, to quantify the eﬀect of systemic alendronate
treatment following a total hip replacement. In this sit-
uation, both mechanical (e.g. stress shielding eﬀect) and
chemical (drug eﬀect) parameters have to be accounted
for simultaneously. Moreover, with the proposed model,
it would be possible to compare from a quantitative
point of view the eﬀect of diﬀerent drugs on bone re-
modeling and to establish a numerical comparison.
In this study, it has been assumed that alendronate
treatments had no eﬀect on the bone formation pa-
rameters. Experimentally, it has been observed that be-
side resorption, formation may also decrease when
bisphosphonates was used (Rodan and Fleisch, 1996).
Nevertheless, no evidence for reduced osteoblastic ac-
tivity at individual bone formation sites was found.
Speciﬁcally, eﬀect of alendronate on bone formation has
not been observed (Chavassieux et al., 1997). Moreover
no adverse eﬀects on bone structure or mineralizationwas observed, alendronate preserved the biomechanical
properties of the bone.
Few studies have tried to theoretically evaluate the
eﬀect of drugs on bone remodeling. A mathematical
model has shown that the ﬂuoride uptake by skeleton
was associated with bone remodeling (Turner et al.,
1993). Sensitivity analysis of a bone turnover computer
model showed that, in case of antiresorptive drugs,
maximal eﬀects on bone volume may be achieved by
pharmacologically reducing the activation frequency of
bone remodeling units (Lacy et al., 1994). Recently, a
study using a computer simulation of bone remodeling
evaluated the eﬀect of alendronate treatment (Heaney
et al., 1997). It has been found that improvement of bone
density by alendronate treatment could be explained by
combinations of suppression of bone remodeling acti-
vation and positive remodeling balance. The inﬂuences
of focal bone balance and ash fraction during alendro-
nate treatment have also been compared using a com-
puter simulation of bone remodeling (Hernandez et al.,
2001). However, none of these previous studies allowed
to incorporate simultaneously in one framework bio-
mechanical and drug eﬀects. The present study was
speciﬁcally developed for this purpose. It is important to
combine these two aspects as mechanical forces are in-
evitably present in every daily activities.
A major advantage of the proposed model is that the
description is not related to a particular mechanical
stimulus. Based on the generally accepted concept of
bone remodeling using the lazy zone approach (Cowin,
1987; Frost, 1983), several mechanical stimuli have been
developed to model the bone remodeling (Huiskes et al.,
1987; Terrier et al., 1997). The present description of the
alendronate eﬀect is general enough to be used in diﬀerent
proposed models based on the lazy zone concept of bone
remodeling. Moreover, the developed approach could be
generalized to other drugs aﬀecting bone remodeling. For
example, other bisphosphonates such as zoledronate and
pamidronate (Pataki et al., 1997), diﬀerent treatments
inhibiting bone resorption such as calcitonin (Rodan and
Martin, 2000) or recently interferon-b (Takayanagi et al.,
2002), or even treatment favoring bone formation such as
BMPs (Service, 2000) could be evaluated with the de-
veloped model if the BMD evolution is known. A nu-
merical description of diﬀerent drug eﬀects on bone
remodeling could then be performed.
In conclusion, we showed that continuous BMD in-
crease following bisphosphonates treatment may be
explained by biomechanical considerations. Bisphosph-
onates may increase the equilibrium bone remodeling
zone on the resorption side in a dose dependent rela-
tionship in the developed model. Based on this de-
scription, bisphosphonates treatment may indeed
change the susceptibility of bone to its biomechanical
environment decreasing the mechanical threshold where
bone should undergo resorption.
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